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Abstract 
Background: We previously demonstrated that endothelial microparticles (EMPs) are increased in mitral valve dis‑
eases and impair valvular endothelial cell function. Perioperative systemic inflammation is an important risk factor and 
complication of cardiac surgery. In this study, we investigate whether EMPs increase in congenital heart diseases to 
promote inflammation and endothelial dysfunction.
Methods: The level of plasma EMPs in 20 patients with atrial septal defect (ASD), 23 patients with ventricular sep‑
tal defect (VSD), and 30 healthy subjects were analyzed by flow cytometry. EMPs generated from human umbilical 
vascular endothelial cells (HUVECs) were injected into C57BL6 mice, or cultured with HUVECs without or with siRNAs 
targeting P38 MAPK. The expression and/or phosphorylation of endothelial nitric oxide synthase (eNOS), P38 MAPK, 
and caveolin‑1 in mouse heart and/or in cultured HUVECs were determined. We evaluated generation of nitric oxide 
(NO) in mouse hearts, and levels of tumor necrosis factor‑α (TNF‑α) and interleukin‑6 (IL‑6) in cultured HUVECs and in 
mice.
Results: EMPs were significantly elevated in patients with ASD and VSD, especially in those with pulmonary hyper‑
tension when compared with controls. EMPs increased caveolin‑1 expression and P38 MAPK phosphorylation and 
decreased eNOS phosphorylation and NO production in mouse hearts. EMPs stimulated P38 MAPK expression, TNF‑α 
and IL‑6 production, which were all inhibited by siRNAs targeting P38 MAPK in cultured HUVECs.
Conclusions: EMPs were increased in adult patients with congenital heart diseases and may contribute to increased 
inflammation leading to endothelial dysfunction via P38 MAPK‑dependent pathways. This novel data provides a 
potential therapeutic target to address important complications of surgery of congenial heart disease.
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Background
Recently, we demonstrated that circulating microparticles 
in patients with valvular heart disease impaired endothe-
lium dependent vasodilation by uncoupling and inhibiting 
endothelial nitric oxide synthase (eNOS) [1]. Micro-
particles are generated from a variety of sources includ-
ing endothelial cells, platelets, T cells, etc. We previously 
showed that microparticles generated from endothelial 
cells induce acute lung injury, inhibit angiogenesis, and 
impair vasodilation [2, 3]. We also demonstrated that the 
number of plasma endothelial microparticles (EMPs) is 
significantly higher in patients with mitral valve diseases 
leading to impairment of human mitral valve endothelial 
cell function [4]. In proteomics studies, we found that 
EMPs contain hundreds of proteins, some of which may 
impair vasodilation, induce lung injury and/or activate 
inflammation [5, 6]. Thus, EMPs are considered both a 
marker and a mediator of endothelial injury. Previously 
Amabile reported that EMP levels are correlated with 
pulmonary arterial pressure in adults with primary and 
secondary pulmonary arterial hypertension [7]. However, 
Samadja showed no significant difference in EMPs levels 
between irreversible and reversible pulmonary arterial 
hypertension in children with congenital heart disease [8]. 
Thus, whether EMPs are consistently elevated in all con-
genital heart diseases remains unclear.
Perioperative systemic inflammation is a major risk fac-
tor and complication of cardiac surgery. Cardiac surgery 
with cardiopulmonary bypass (CPB) results in systemic 
inflammatory responses that contribute to instability 
of circulation post-operatively [9, 10]. Preventza et  al. 
reported that CPB time is related to mortality after sur-
gery [11]. Although we previously demonstrated that 
EMPs contain proteins that can induce inflammation, the 
impact and the mechanisms of action of EMPs to pro-
mote an inflammatory response are not fully understood. 
In this study, we investigated, for the first time, whether 
EMPs increased in two common congenital heart dis-
eases, atrial septal defect (ASD) and ventricular septal 
defect (VSD), and the impact and the mechanisms of 
action of EMPs to promote inflammation and subsequent 
endothelial dysfunction.
Methods
Please refer to the Additional file 1 for additional details 
on the methodology.
Study population
20 patients diagnosed with ASD, 23 patients with VSD, 
and 30 age-matched healthy volunteer control subjects 
were recruited at The First Affiliated Hospital of Sun 
Yat-sen University. Patients with diseases which may 
increase EMPs level, including coronary heart disease, 
hypertension, infectious disease, severe trauma, antibiotic 
therapy, lupus anticoagulant, multiple sclerosis, renal fail-
ure, rheumatic diseases in acute stage, and valvular heart 
disease were explicitly excluded. Healthy volunteers below 
18 years old and those who abused alcohol and/or heavy 
smokers were excluded. This study was approved by the 
Ethics Committee of The First Affiliated Hospital, Sun 
Yat-sen University. Informed consent was obtained from 
all subjects enrolled in this study. Clinical characteristics, 
doppler echocardiographic metrics (the definition and 
classification of pulmonary hypertension are referenced 
as in the 2014 Nice Pulmonary Hypertension Classifica-
tion System) and operation data were collected (Table 1).
Blood sampling and flow cytometry
All patients preoperatively fasted overnight as did healthy 
volunteers. Blood samples were drawn and centrifuged to 
obtain platelet-poor plasma (PPP) [4]. 50 μL of PPP was 
incubated with 4  μl of anti-CD31-PE and 4  μL of anti-
CD42b-FITC antibodies at room temperature for 20 min 
with gentle orbital shaking in the dark [4]. The samples 
incubated with corresponding isotype control (all from 
Beckman Coulter, France) were used as controls. After 
labeling, samples were analyzed via MoFlo XDP (Beck-
man coulter) by an independent examiner who was 
blinded to study arm and intentions. Before analysis, 
50  μL flow count calibrator beads (Beckman Coulter) 
with known concentration provided by the manufacturer 
were added into the antibody-labeled tubes. After exclud-
ing non-specific fluorescence, those positively labeled by 
anti-CD31-PE and negatively labeled by anti-CD42b-
FITC and <1 μm in size were considered to be EMPs [4].
Generation of EMPs
EMPs were generated ex  vivo by incubating human 
umbilical vein endothelial cells (HUVECs) with plas-
minogen activated inhibitor-1 (PAI-1) as previously 
described [2–6]. Briefly, passage 4 HUVECs were grown 
to confluence in T75 flasks coated with 1% gelatin in 
endothelial cell growth medium-2 (Clonetics) containing 
20% fetal bovine serum. Cultured cells were maintained 
at 37  °C in 5% humidified CO2. After serum starvation, 
cells were stimulated with 10 ng/mL human PAI-1. Three 
hours later, the EMPs-rich supernatant was collected 
and centrifuged (300×g, 10  min) to remove cell debris. 
The supernatant was removed after ultracentrifugation 
(105×g, 60  min) and EMPs were resuspended in phos-
phate-buffered saline (PBS) at room temperature for sub-
sequent experiments.
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SiRNA targeting P38 MAPK
To confirm the relationship between EMPs and the P38 
MAPK pathway, we used targeted siRNAs to reduce 
expression of P38 MAPK in HUVECs. HUVECs were 
cultured in endothelial cell medium (ScienCell) supple-
mented with 5% Fetal bovine serum (FBS), 1% growth 
factors, and 1% penicillin/streptomycin. Cells were serum 
starved in 0.5% FBS over night before experiments. Tar-
geted SiRNAs and scrambled siRNAs (negative con-
trol) (Dharmacon, MA) were transfected into cells with 
siPORT™ NeoFX™ Transfection Agent (Invitrogen, USA) 
and Opti-MEM I (Gibco). InitialsiRNA concentrations 
used were 70  nM. At 12  h after transfection, medium 
was exchanged with endothelial cell medium (Sciencell, 
Carlsbad, CA) consisting of 10% Fetal bovine serum and 
10 ng/mL epidermal growth factor to remove siRNA. A 
separate control group containing only with siPORT™ 
NeoFX™ Transfection Agent and Opti-MEM I was also 
employed.
ELISA for cell cultures
After siRNA transfection, HUVECs were cultured for an 
additional 48–72  h until the monolayer of cells reached 
90–100% confluence. The cultured cells were then serum 
starved overnight and stimulated with EMPs (2  ×  105/
mL) for 6  h. After centrifuging for 20  min at 12,000×g, 
the supernatants were collected and tumor necrosis 
factor-α (TNF-α) and interleukin (IL)-6 levels were eval-
uated using ELISA kits (ebioscience) as recommended in 
the manufacturer’s protocol.
Animal experiments
All animal experiments were approved by the Animal 
Ethics Commission of the First Affiliated Hospital of 
Sun Yat-sen University. The investigation conformed 
to the provisions of the Declaration of Helsinki in 1995 
(as revised in Edinburgh 2000). Eight-week-old female 
C57BL6 mice were obtained from the animal center 
of Sun Yat-sen University, north campus. 1  ×  105 or 
5  ×  105/mL EMPs were injected into the mice via tail 
vein. Those injected with an equal volume of PBS were 
used as controls. 6  h after injection, mice were fully 
anesthetized with sodium pentobarbital (50  mg/kg) and 
blood samples were drawn for measurement of pro-
inflammatory factors. In addition, the heart was isolated 
and frozen in liquid nitrogen for further immunoblotting 
analysis and immunohistochemical staining as previously 
described [3, 12, 13].
ELISA for plasma
The blood samples drawn from mice were centrifuged 
and plasma was isolated. TNF-α and IL-6 concentrations 
were determined using ELISA kits (ebioscience).
Immunoblotting analysis
To investigate the effects of EMPs on relevant proteins 
in the mouse heart, eNOS expression and phosphoryla-
tion at Ser1177, P38 MAPK expression and phospho-
rylation, and expression of caveolin-1 were assessed by 
immunoblotting with specific antibodies as previously 
described [3].
Table 1 Clinical characteristic and Doppler echocardiographic variables
Values are expressed as mean ± standard deviation
PH pulmonary hypertension, NYHA New York Heart Association, CPB cardiopulmonary bypass, LAD left atrial diameter, LVEDD left ventricular end-diastolic diameter, 
LVESD left ventricular end-systolic diameter, RAD right atrial diameter, RVD right ventricle diameter, LVEF left ventricular ejection fraction
* P < 0.05 compared with control group
# P < 0.05 compared with atrial septal defect group
Variables Control group Atrial septal defect group Ventricular septal defect group
N 30 20 23
Gender (M/F) 12/18 7/13 10/13
Age (y) 39.87 ± 13.17 35.85 ± 14.12 38.30 ± 14.81
PH, N (%) 0 15 (75%) 6 (26.1%)
NYHA Class (II/III) 0 16/4 15/8
CPB time, min – 66 ± 28 75 ± 23
Aortic cross clamp time, min – 33 ± 24 39 ± 20
LAD, mm 29.93 ± 2.69 33.75 ± 5.11* 36.48 ± 9.98*
LVEDD, mm 45.903.16 39.75 ± 3.89* 51.78 ± 11.43*#
LVESD, mm 28.80 ± 2.72 25.55 ± 2.87* 31.64 ± 8.28#
RAD, mm 33.53 ± 3.67 46.42 ± 8.36* 39.59 ± 11.93
RVD, mm 19.30 ± 2.76 35.35 ± 8.65* 22.22 ± 5.03#
LVEF, % 69.27 ± 6.60 66.65 ± 7.07 68.22 ± 5.87
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To investigate the effects of EMPs and siRNAs on cul-
tured cells, HUVECs were evaluated without and with 
transfection of siRNAs targeting P38 MAPK (and scram-
bled control siRNAs) as described above. HUVECs were 
stimulated with EMPs (2 × 105/mL) for 1 h. Then cellular 
proteins were harvested, total and phosphorylated P38 
MAPK, and GAPDH protein expression were determined 
by immunoblotting as previously described [4, 14].
Antibodies for detection of phosphorylation of eNOS 
at Ser1177, P38 MAPK, phosphorylation of P38 MAPK, 
and caveolin-1 were purchased from Cell Signaling 
Technology (Danvers, MA). Anti-eNOS was obtained 
from Santa Cruz Biotechnology (Santa Cruz, CA). Anti-
GAPDH was obtained from Proteintech Group (Chicago, 
IL). Proteins were separated by SDS-PAGE and then visu-
alized using luminol reagent (Santa Cruz Biotechnology) 
according to standard methods.
Immunohistochemical staining
To investigate the effects of EMPs on relevant pro-
tein expression in mouse hearts, isolated mouse hearts 
treated without or with EMPs were embedded with 
paraffin, sectioned and subjected to immunostaining. 
The expression of caveolin-1, eNOS, and P38 MAPK 
in mouse hearts was detected by immunohistochemi-
cal staining using standard protocols. Polycolonal rabbit 
IgG anti-Caveolin-1 antibody (1:100, Abcam), anti-eNOS 
antibody (1:100, Abcam) and anti-p38 MAPK antibody 
(1:100, Abcam) were used as primary antibodies.
Measurement of nitric oxide (NO) generation
1 ×  105 or 5 ×  105/mL EMPs or equal volumes of PBS 
were injected into the mouse tail vein. 6  h later, hearts 
were isolated and placed in 1:9 (wt/vol) cold homog-
enization buffer. The hearts were cut into small pieces 
with an iris scissors and homogenized five times on ice 
(10 s with 30 s intervals between homogenizations). The 
homogenates were then centrifuged for 8 min (2000 rpm, 
4  °C) and the supernatant was isolated. NO concentra-
tion was determined by measuring total nitrate plus 
nitrite (NO3− + NO2−) using an NO detection kit (Nan-
jing Jiancheng Bioengineering Institute, Nanjing, China) 
according to the manufacturer’s instructions. Briefly, 
nitrate was enzymatically converted into nitrite by nitrate 
reductase, and nitrite was quantified with Griess rea-
gent at an absorbance of 550 nm, as previously described 
[3]. The range of the detection of nitrate plus nitrite is 
0–600  μmol/L according to the manufacturer. In addi-
tion, the total protein concentration of the supernatant 
was determined by bicinchoninic acid protein assay 
(Merck, Whitehouse Station, NJ).
Statistical analysis
Statistical analyses were performed using Prism 5 soft-
ware. For comparison of healthy subjects, ASD patients, 
and VSD patients, or the impact of different concen-
trations of EMPs on protein expression in hearts and 
cultured cells, one-way ANOVA and Newman-Keuls 
comparisons were used. Chi-square test was used to 
compare proportions between different groups. For com-
parison between EMPs and controls, a t test was used. 
P  <  0.05 was considered to indicated statistical signifi-
cance. Data were presented as mean ± SDEM.
Results
Demographic and clinical parameters
Demographic and clinical features are shown in Table 1. 
Age and gender were similar among the three groups of 
subjects. 15 patients with ASD and 6 patients with VSD 
were suffering from pulmonary hypertension. Accord-
ing to New York heart association classification, of the 20 
patients with ASD 16 patients were class II and 4 patients 
were class III. Of 23 patients with VSD, 15 patients were 
class II and 8 patients were class III, respectively. The 
duration of CPB (66 ± 28 vs. 75 ± 23 min) and the time 
of aortic cross clamping (33 ± 24 vs. 39 ± 20 min) were 
similar among ASD group and VSD group during the 
operation, respectively.
Echocardiographic findings
Transthoracic echocardiography differences found 
among the three subject groups are shown in Table 1. The 
control group had no evidence of morphologic heart dis-
ease. When compared with the control group, left atrial 
diameter (LAD), right atrial diameter (RAD) and right 
ventricular diameter (RVD) were significantly enlarged 
in ASD patients; left ventricular end-diastolic diam-
eter (LVEDD), and left ventricular end-systolic diameter 
(LVESD) were significantly smaller in the ASD patients 
group. LAD and LVEDD were significantly enlarged in 
the VSD patients group. When compared with the ASD 
group, LVEDD and LVESD were significantly enlarged 
in the VSD group; RVD was significantly smaller in 
VSD group. There were no significant differences in left 
ventricular ejection fraction among the three groups of 
subjects.
Levels of plasma EMPs
When compared with the control group, plasma EMPs 
levels were significantly elevated in the ASD group and 
VSD group (Fig. 1A). The higher levels of plasma EMPs 
in ASD and VSD patients were positively correlated with 
pulmonary hypertension (Fig. 1B).
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Effects of EMPs on expression of P38 MAPK, Caveolin‑1 
and eNOS in mouse hearts and in HUVECs
In mouse hearts, both immunohistochemical staining 
and immunoblotting showed that EMPs significantly 
increased expression of caveolin-1 (Figs.  2A, B; 3A). 
EMPs dramatically decreased eNOS phosphorylation at 
the S1177 site without altering total eNOS expression 
(Figs. 2C, D; 3B).
Both immunohistochemical staining and immunob-
lotting showed that EMPs dramatically increased P38 
MAPK phosphorylation (Fig.  4). EMPs also stimulated 
increased expression of P38 MAPK in HUVECs. This was 
substantially inhibited by siRNAs targeting P38 MAPK 
(Fig. 5A, B).
Effects of EMPs on TNF‑α and IL‑6 concentrations 
in cultured HUVECs
EMPs significantly stimulated an increase in TNF-α con-
centration in cultured HUVECs. In EMPs stimulated 
groups, TNF-α concentration in the group transfected 
with siRNA targeting P38 MAPK was significantly lower 
than in cells transfected with the scrambled siRNA con-
trol. No differences were observed between control siRNA 
and cells not treated with siRNA (Fig. 5C). A similar pat-
tern was observed with concentrations of IL-6 (Fig 5D).
Effects of EMPs on TNF‑α and IL‑6 concentrations in mouse 
plasma
As shown in Fig. 6A and B, TNF-α and IL-6 concentra-
tions in the plasma of mice were significantly increased 
after intravenous injection with EMPs 5 × 105/mL for 6 h 
(when compared with controls).
Effects of EMPs on NO generation in mouse hearts
As shown in Fig.  6C, NO concentration in the mouse 
hearts treated with EMPs was significantly decreased 
when compared with controls. There was a dose-depend-
ent effect of EMPs to stimulate NO production in mouse 
hearts (Fig. 6C).
Discussion
We and others have previously demonstrated that EMPs 
levels are elevated in patients with valvular heart dis-
eases and this contributes to impairing mitral valve 
endothelial cell function [4]. We further showed that 
circulating microparticles generated from patients with 
valvular heart disease and cardiac surgery can contribute 
to endothelial dysfunction [1]. In the present study, we 
are first to show that EMPs levels are also increased in 
adult patients with ASD and VSD resulting in increased 
inflammation and endothelial dysfunction. This indicates 
that EMPs are not only increased in acquired heart dis-
eases, but also elevated in simple acyanotic congenital 
heart diseases where it may play a pathophysiological 
role.
The mechanisms underlying increased numbers 
of plasma EMPs in ASD and VSD are unclear. Previ-
ous studies demonstrated that EMPs can be released 
from endothelial cell activation and/or apoptosis [15]. 
The atrium and ventricle sizes were increased in ASD 
and VSD patients. These changes and additional septal 
defects lead to hemodynamics change and shear stress 
that may potentially contribute to EMP formation [15, 
16]. Shear stress is a major determinant of endothe-
lial damage which may induce activation of endothelial 
Fig. 1 EMPs increase in patients with atrial septal defect and ventricular septal defect. A Compared with control group, EMPs were increased in 
patients with ASD and VSD. B EMPs were increased in patients with ASD and VSD associated with pulmonary hypertension (PH) than those without 
PH. *P < 0.05 compared with control group. #P < 0.05 compared with ASD and VSD patients
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cells and lead to EMPs release [16]. It is also possible 
that abnormal hemodynamic forces including abnormal 
blood flow through cardiac defects and increased blood 
flow in cardiopulmonary circulation may stimulate EMPs 
release [15].
Pulmonary hypertension is one major complications of 
congenital heart diseases [17, 18]. In the present study, 
we found that levels of EMPs were higher in patients 
with ASD and VSD accompanied by pulmonary hyper-
tension than in those without pulmonary hypertension. 
Endothelial cell activation and apoptosis is observed in 
patients with pulmonary hypertension [19, 20] leading 
to increases in pulmonary blood flow that exert abnor-
mal shear stress and result in endothelial dysfunction in 
lamb models [21]. These abnormalities may cause more 
EMPs release in ASD and VSD patients with pulmonary 
hypertension than in isolated ASD and VSD patients 
without pulmonary hypertension. Samadja reported no 
significant differences in EMPs level between irreversible 
and reversible pulmonary  arterial  hypertension in chil-
dren with congenital heart diseases. Thus, it is possible 
that EMPs levels increase when pulmonary hyperten-
sion occurs but does not further increase upon progres-
sion to irreversible pulmonary arterial hypertension. This 
may be due to the fact that endothelial cells are already 
activated to release EMPs at a maximal rate in reversible 
pulmonary hypertension and further increases to gen-
erate more EMPs do not occur as disease progresses to 
the irreversible state. Taken together, this data suggests 
that increased level of EMPs may be a predictor for pul-
monary hypertension in congenital heart disease [22]. 
Indeed, EMPs are already considered as marker of many 
other diseases. Our findings extend these previous results 
to suggest that EMPs may also be a biomarker of pulmo-
nary hypertension in adult congenital heart diseases and 
congenital heart diseases per se.
We and others have been demonstrated that EMPs may 
play an important role in exacerbating endothelial dys-
function [2–4, 7]. It is well known that eNOS-mediated 
NO production plays a critical role in the regulation of 
endothelial function [23, 24]. To investigate the mecha-
nisms by which EMPs impair endothelial function, we 
performed some basic studies in mice and endothelial 
cells. We found that EMPs significantly inhibited eNOS 
phosphorylation and NO production in mouse hearts 
in a dose-dependent manner. Caveolin-1 binds to eNOS 
to keep eNOS in an inactive state [23]. We found that 
caveolin-1 expression in mouse hearts was increased by 
Fig. 2 Effects of EMPs on Caveolin‑1 and eNOS in the mouse hearts. A–D Immunohistochemical staining showed that EMPs can increase the 
expression of caveolin‑1 and decrease the expression of phosphorylation of eNOS in the mouse hearts
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EMPs in a dose-dependent manner. This suggests that 
EMPs may inhibit eNOS activity to block NO generation 
in mice hearts through an increase in caveolin-1 expres-
sion. As reduction of NO bioactivity is a hallmark of 
endothelial dysfunction, our findings indicate that EMPs 
may inhibit eNOS activity to reduce NO to contribute 
to endothelial dysfunction in hearts. It should be noted 
that iNOS is another major source of NO. EMPs may 
also inhibit iNOS to produce NO. However, we found 
that EMPs didn’t inhibit iNOS expression in the healthy 
and hypercholesterolemic mice hearts in both the cur-
rent study and previous study (data not shown) [3]. This 
suggests that iNOS is probably not a major contributor to 
NO reduction observed in our studies. We recently dem-
onstrated that circulating microparticles from valvular 
heart diseases and cardiac surgery can inhibit NO gener-
ation to impair endothelium dependent vasodilation [1]. 
As EMPs are part of circulating microparticles, our find-
ings that plasma EMPs level increased and EMPs inhibit 
NO generation in the hearts suggest that EMPs may 
affect hemodynamic stability in patients with ASD and 
VSD post cardiac surgery. In addition, as EMPs inhibit 
NO production, this may also exacerbate the develop-
ment of pulmonary hypertension leading to a further 
increase in EMPs.
Perioperative systemic inflammation is one of the 
major risk factors and complications in cardiac surgery. 
P38 MAPK signaling mediates myocardial inflammatory 
responses and endothelial dysfunction that can contrib-
ute to myocardial damage following acute injury [25, 
26]. P38 MAPK signaling pathway also plays a vital role 
in the formation and maturation process of EMPs [27]. 
In the present study, our data showed that phosphoryla-
tion of p38 MAPK in mouse hearts was increased by 
EMPs in a dose-dependent manner. This suggests that 
EMPs can activate the P38 MAPK pathway. We further 
found that EMPs also increased P38 MAPK expression 
and stimulated increases in TNF-α and IL-6 levels both 
in cultured endothelial cells and mice. The increased 
P38 MAPK expression as well as downstream TNF-α 
and IL-6 production was inhibited by disrupting the p38 
MAPK pathway with targeted specific siRNAs. This sug-
gests that EMPs stimulate TNF-α and IL-6 production 
using a P38 MAPK-dependent pathway consistent with 
Fig. 3 Effects of EMPs on Caveolin‑1 and eNOS in the mouse hearts. A, B Immunoblotting showed that EMPs were significantly increased expres‑
sion of caveolin‑1 and decreased eNOS phosphorylation at S1177 site with a dose‑dependent effect without altering the eNOS expression in the 
mouse hearts. (*P < 0.05 compared with control group. #P < 0.05 compared with group of EMPs 105/mL, n = 8)
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other studies of pro-inflammatory signaling related to 
TNF-α and IL-6 production [26, 28]. In some studies, 
EMPs level is correlated with serum IL-6 level, in both 
healthy subjects and in patients with coronary heart 
disease [29, 30]. In  vitro studies show that inflamma-
tory factors induce endothelial cell apoptosis leading to 
production of EMPs. Our study showed that EMPs can 
induce endothelial cells to release pro-inflammatory fac-
tors in a P38 MAPK-dependent fashion. Thus, EMPs may 
be both the cause and consequence of pro-inflammatory 
responses in a feed-forward mechanism that amplifies 
inflammation and its pathophysiological consequences. 
This raises the possibility that blocking EMPs’ function 
or reducing EMPs’ level may be a potential therapeutic 
strategy for controlling inflammation in congenital heart 
disease. Since TNF-α and IL-6 are secretory mediators 
and proinflammatory cytokines that increase endothelial 
cell permeability and promote endothelial cell activation, 
dysfunction, and apoptosis [25, 26], our data suggests 
that EMPs may induce inflammation to impair endothe-
lial function and damage vascular endothelial cells by 
activating the P38 MAPK pathway to promote TNF-α 
and IL-6 production. Thus, future studies will be inves-
tigated whether EMPs upregulate some gene expressions 
to activate P38 MAPK pathway in endothelial cells.
Study Limitations: Due to the limitations in current 
technology, we are unable to extract EMPs from patients’ 
plasma directly to perform animal or cell studies. Instead, 
in the present study, we have relied on a published strat-
egy to obtain EMPs from cultured endothelial cells 
Fig. 4 EMPs increased P38 phosphorylation in the mouse hearts. A, B Immunohistochemical staining showed that EMPs can increase the phospho‑
rylation of P38 in the mouse hearts. C, D Immunoblotting showed that EMPs were dramatically increased P38 phosphorylation with a dose‑
dependent effect. (*P < 0.05 compared with control group, #P < 0.05 compared with the group of EMPs 105/mL, n = 8)
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stimulated with PAI-1 [2, 4, 6] that may cause xenotrans-
plant-type reactions. In addition, HUVECs used in the 
present study may not be representative of all human 
endothelial cell types and components of EMPs from dif-
ferent endothelial cell sources may have different func-
tional abilities with diverse biological functions [5, 6]. 
Thus, EMPs used in the current study may have some dif-
ferences from EMPs in congenital heart disease patients. 
Furthermore, the mice used in the current study were 
healthy mice and its physiology may not represent human 
congenital heart disease (patho) physiology. However, 
the primary goal of the present study was to determine 
effects of EMPs on mouse heart, independent of pathol-
ogy. If EMPs can adversely affect healthy hearts, it seems 
plausible that effects of EMPs in congenital heart disease 
may be even more severe. Our data clearly demonstrated 
EMPs impaired heart function. We only tested effects of 
EMPs on endothelial cells because we wanted to focus 
on endothelial function, a major line of investigation in 
our lab. This represents an additional study limitation. 
Whether EMPs have similar effects on human cardio-
myocytes needs to be evaluated in subsequent studies 
beyond the scope of the present study. Based on our pre-
vious findings and other publications [1–6], we speculate 
that EMPs may induce inflammation leading to endothe-
lial dysfunction in patients with congenital heart diseases. 
Identifying and evaluating safe P38 MAPK inhibitors to 
block P38 MAPK-dependent pathways in vivo as a poten-
tial therapeutic strategy to decrease EMPs are beyond the 
scope of the present study but are the subject of future 
Fig. 5 EMPs can stimulate TNF‑α and IL‑6 release in HUVECs, which can be down‑regulated by P38‑siRNAs. A, B Immunoblotting showed EMPs can 
increase P38 expression, which can be reduced by siRNAs targeting P38 MAPK (Si‑P38). C, D TNF‑α and IL‑6 concentration were relative low in con‑
trol (C) and negative (Neg) group. After 6 h stimulated with EMPs, TNF‑α and IL‑6 level increased in each group. TNF‑α and IL‑6 level in siRNAs P38 
MAPK group was significantly lower than that in non‑P38 siRNAs interfering groups. (*P < 0.05 compared with control group, **P < 0.05 compared 
with negative group, ***P < 0.05 compared with the group of EMPs 105/mL, n = 8)
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studies in our lab. Other future related studies include 
evaluating relationships between EMPs level and cardio-
pulmonary bypass, deep hypothermic circulatory arrest, 
and postoperative complications.
Conclusions
In summary, our study demonstrated that EMPs were 
increased in adult patients with congenital heart dis-
eases. These increased EMPs inhibited eNOS activity 
to reduce NO production and activated P38 MAPK-
dependent signaling pathways to promote production 
of TNF-α and IL-6. These mediators of pro-inflam-
matory response impaired endothelial function. These 
changes may contribute to impairment of myocardial 
and vascular function during the perioperative period 
to affect hemodynamic stability after cardiac surgery. 
In addition, the consequences of increased EMPs may 
also promote development of pulmonary hyperten-
sion. We conclude that the P38 MAPK pathway may 
play a role in EMPs-induced inflammation and provide 
a potential therapeutic target in surgery of congenial 
heart disease.
Abbreviations
EMPs: endothelial microparticles; ASD: atrial septal defect; VSD: ventricular 
septal defect; HUVECs: human umbilical vascular endothelial cells; eNOS: 
endothelial nitric oxide synthase; TNF‑α: tumor necrosis factor‑α; IL‑1: interleu‑
kin‑1; CPB: cardiopulmonary bypass; NO: nitric oxide; NYHA: New York Heart 
Association; LAD: left atrial diameter; LVEDD: left ventricular end‑diastolic 
diameter; LVESD: left ventricular end‑systolic diameter; RAD: right atrial diam‑
eter; RVD: right ventricle diameter; LVEF: left ventricular ejection fraction.
Additional file
Additional file 1. Online supplemental materials and methods.
Fig. 6 EMPs increased TNF‑α and IL‑6 release in mouse and decreased NO generation in the mouse hearts. A, B The levels of TNF‑α and IL‑6 in 
mouse plasma in EMPs group (5 × 105/mL) were significantly higher than that in control groups. (*P < 0.05 compared with control group, n = 8).  
C EMPs significantly decrease NO production in the mouse hearts. The group of EMPs (5 × 105/mL) was released NO less than the group of EMPs 
(105/mL). (*P < 0.05 compared with control group, #P < 0.05 compared with group of EMPs (105/mL), n = 12)
Page 11 of 12Lin et al. J Transl Med  (2017) 15:4 
Authors’ contributions
ZBL, HBC mainly performed the cell culture and animal experiments. They 
also drafted the manuscript. YL, TPC, HML, JC, YSW and HXY performed part 
of the cell culture and animal experiments and analyzed part of the data. DHL 
performed the Doppler echocardiography study. LZ, ZPW and XZ performed 
the human study and analyzed and interpreted this part of data. ZJO, JSO and 
JX mainly contributed to the conception and design of the work, interpreted 
the data, and revised the manuscript. All authors read and approved the final 
manuscript.
Author details
1 Division of Cardiac Surgery, The First Affiliated Hospital of Sun Yat‑sen Univer‑
sity, 58 Zhong Shan Er Road, Guangzhou 510080, People’s Republic of China. 
2 Department of Ultrasound, The First Affiliated Hospital of Sun Yat‑sen Univer‑
sity, Guangzhou 510080, People’s Republic of China. 3 Division of Hypertension 
and Vascular Diseases, The First Affiliated Hospital of Sun Yat‑sen University, 
Guangzhou 510080, People’s Republic of China. 4 The Key Laboratory 
of Assisted Circulation, Ministry of Health, Guangzhou 510080, People’s Repub‑
lic of China. 5 National and Guangdong Province Joint Engineering Laboratory 
for Diagnosis and Treatment of Vascular Diseases, Guangzhou 510080, People’s 
Republic of China. 6 Guangdong Provincial Key Laboratory of Brain Function 
and Disease, Guangzhou 510080, People’s Republic of China. 7 State Key Labo‑
ratory of Respiratory Disease, Guangzhou 510080, People’s Republic of China. 
8 Guangzhou Institute of Respiratory Disease, Guangzhou 510080, People’s 
Republic of China. 9 The First Affiliated Hospital of Guangzhou Medical Univer‑
sity Guangzhou, Guangzhou 510120, People’s Republic of China. 
Acknowledgements
We thank the patients and staffs at the First Affiliated Hospital, Sun Yat‑sen 
University for their assistance throughout this study.
Competing interests
The authors declare that they have no competing interests.
Availability of data and materials section
The dataset(s) supporting the conclusions of this article is (are) included 
within the article. All clinical data are stored by information system at Division 
of Cardiac Surgery, The First Affiliated Hospital of Sun Yat‑sen University.
Ethics approval and consent to participate
The research was permitted by the ethics committee of The First Affiliated 
Hospital of Sun Yat‑sen University and written informed consents were 
obtained from all patients.
Funding
This study was supported by the National Natural Science Foundation of 
China (81170271, 81370370, 81500215, 81600382, 81670392 and Dis‑
tinguished Young Scholar 81325001), the Changjiang Scholars Program 
from Ministry of Education of China, the Guangdong Pearl River Scholars 
Program, 973 project (2009CB522104) and International Cooperation Project 
(2015DFA31070) from the Ministry of Science and Technology of China, 
Guangdong Natural Science Fund Committee, China (2015A030312009), Sun 
Yat‑Sen University Clinical Research 5010 Program; Program of National Key 
Clinical Specialties.
Received: 13 July 2016   Accepted: 18 November 2016
References
 1. Fu L, Hu XX, Lin ZB, Chang FJ, Ou ZJ, Wang ZP, Ou JS. Circulating micro‑
particles from patients with valvular heart disease and cardiac surgery 
inhibit endothelium‑dependent vasodilation. J Thorac Cardiovasc Surg. 
2015;150(3):666–72.
 2. Densmore JC, Signorino PR, Ou J, Hatoum OA, Rowe JJ, Shi Y, Kaul S, 
Jones DW, Sabina RE, Pritchard KA Jr, et al. Endothelium‑derived micro‑
particles induce endothelial dysfunction and acute lung injury. Shock. 
2006;26(5):464–71.
 3. Ou ZJ, Chang FJ, Luo D, Liao XL, Wang ZP, Zhang X, Xu YQ, Ou JS. 
Endothelium‑derived microparticles inhibit angiogenesis in the heart 
and enhance the inhibitory effects of hypercholesterolemia on angio‑
genesis. Am J Physiol Endocrinol Metab. 2011;300(4):E661–8.
 4. Ci HB, Ou ZJ, Chang FJ, Liu DH, He GW, Xu Z, Yuan HY, Wang ZP, Zhang 
X, Ou JS. Endothelial microparticles increase in mitral valve disease and 
impair mitral valve endothelial function. Am J Physiol Endocrinol Metab. 
2013;304(7):E695–702.
 5. Peterson DB, Sander T, Kaul S, Wakim BT, Halligan B, Twigger S, Pritchard 
KA Jr, Oldham KT, Ou JS. Comparative proteomic analysis of PAI‑1 and TNF‑
alpha‑derived endothelial microparticles. Proteomics. 2008;8(12):2430–46.
 6. Sander TL, Ou JS, Densmore JC, Kaul S, Matus I, Twigger S, Halligan B, 
Greene AS, Pritchard KA Jr, Oldham KT. Protein composition of plasmino‑
gen activator inhibitor type 1‑derived endothelial microparticles. Shock. 
2008;29(4):504–11.
 7. Amabile N, Heiss C, Real WM, Minasi P, McGlothlin D, Rame EJ, Grossman 
W, De Marco T, Yeghiazarians Y. Circulating endothelial microparticle 
levels predict hemodynamic severity of pulmonary hypertension. Am J 
Respir Crit Care Med. 2008;177(11):1268–75.
 8. Smadja DM, Gaussem P, Mauge L, Lacroix R, Gandrille S, Remones V, 
Peyrard S, Sabatier F, Bonnet D, Levy M. Comparison of endothelial bio‑
markers according to reversibility of pulmonary hypertension secondary 
to congenital heart disease. Pediatr Cardiol. 2010;31(5):657–62.
 9. He GW. Endothelial function related to vascular tone in cardiac surgery. 
Heart Lung Circ. 2005;14(1):13–8.
 10. Floh AA, Manlhiot C, Redington AN, McCrindle BW, Clarizia NA, Caldarone 
CA, Schwartz SM. Insulin resistance and inflammation are a cause of 
hyperglycemia after pediatric cardiopulmonary bypass surgery. J Thorac 
Cardiovasc Surg. 2015;150(3):498–504.
 11. Preventza O, Garcia A, Cooley DA, Tuluca A, Simpson KH, Bakaeen FG, 
Omer S, Cornwell L, Rosengart TK, Coselli JS. Reoperations on the total 
aortic arch in 119 patients: short‑ and mid‑term outcomes, focusing on 
composite adverse outcomes and survival analysis. J Thorac Cardiovasc 
Surg. 2014;148(6):2967–72.
 12. Barst RJ, Ertel SI, Beghetti M, Ivy DD. Pulmonary arterial hypertension: a 
comparison between children and adults. Eur Respir J. 2011;37(3):665–77.
 13. Almansob MA, Xu B, Zhou L, Hu XX, Chen W, Chang FJ, Ci HB, Yao JP, 
Xu YQ, Yao FJ, et al. Simvastatin reduces myocardial injury undergoing 
noncoronary artery cardiac surgery: a randomized controlled trial. Arte‑
rioscler Thromb Vasc Biol. 2012;32(9):2304–13.
 14. Chang FJ, Yuan HY, Hu XX, Ou ZJ, Fu L, Lin ZB, Wang ZP, Wang SM, Zhou 
L, Xu YQ, et al. High density lipoprotein from patients with valvular heart 
disease uncouples endothelial nitric oxide synthase. J Mol Cell Cardiol. 
2014;74:209–19.
 15. Jenkins NT, Padilla J, Boyle LJ, Credeur DP, Laughlin MH, Fadel PJ. 
Disturbed blood flow acutely induces activation and apoptosis of the 
human vascular endothelium. Hypertension. 2013;61(3):615–21.
 16. Vion AC, Ramkhelawon B, Loyer X, Chironi G, Devue C, Loirand G, Tedgui 
A, Lehoux S, Boulanger CM. Shear stress regulates endothelial microparti‑
cle release. Circ Res. 2013;112(10):1323–33.
 17. Opotowsky AR. Clinical evaluation and management of pulmonary 
hypertension in the adult with congenital heart disease. Circulation. 
2015;131(2):200–10.
 18. Latus H, Yerebakan C, Schranz D, Akintuerk H. Right ventricular 
failure from severe pulmonary hypertension after surgery for shone 
complex: back to fetal physiology with reducting, atrioseptectomy, 
and bilateral pulmonary arterial banding. J Thorac Cardiovasc Surg. 
2014;148(5):e226–8.
 19. White K, Dempsie Y, Caruso P, Wallace E, McDonald RA, Stevens H, Hatley 
ME, Van Rooij E, Morrell NW, MacLean MR, et al. Endothelial apoptosis in 
pulmonary hypertension is controlled by a microRNA/programmed cell 
death 4/caspase‑3 axis. Hypertension. 2014;64(1):185–94.
 20. Tian W, Jiang X, Tamosiuniene R, Sung YK, Qian J, Dhillon G, Gera L, Farkas 
L, Rabinovitch M, Zamanian RT, et al. Blocking macrophage leukotriene 
b4 prevents endothelial injury and reverses pulmonary hypertension. Sci 
Transl Med. 2013;5(200):200ra117.
 21. Tian J, Fratz S, Hou Y, Lu Q, Gorlach A, Hess J, Schreiber C, Datar SA, Oishi 
P, Nechtman J, et al. Delineating the angiogenic gene expression profile 
before pulmonary vascular remodeling in a lamb model of congenital 
heart disease. Physiol Genomics. 2011;43(2):87–98.
Page 12 of 12Lin et al. J Transl Med  (2017) 15:4 
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
 22. Diehl P, Aleker M, Helbing T, Sossong V, Germann M, Sorichter S, Bode C, 
Moser M. Increased platelet, leukocyte and endothelial microparticles 
predict enhanced coagulation and vascular inflammation in pulmonary 
hypertension. J Thromb Thrombolysis. 2011;31(2):173–9.
 23. Chen Z, Bakhshi FR, Shajahan AN, Sharma T, Mao M, Trane A, Bernatchez 
P, van Nieuw Amerongen GP, Bonini MG, Skidgel RA, et al. Nitric oxide‑
dependent Src activation and resultant caveolin‑1 phosphorylation 
promote eNOS/caveolin‑1 binding and eNOS inhibition. Mol Biol Cell. 
2012;23(7):1388–98.
 24. Xuan C, Chang FJ, Liu XC, Bai XY, Liao XL, He GW, Ou JS. Endothelial nitric 
oxide synthase enhancer for protection of endothelial function from 
asymmetric dimethylarginine‑induced injury in human internal thoracic 
artery. J Thorac Cardiovasc Surg. 2012;144(3):697–703.
 25. Sarov‑Blat L, Morgan JM, Fernandez P, James R, Fang Z, Hurle MR, 
Baidoo C, Willette RN, Lepore JJ, Jensen SE, et al. Inhibition of p38 
mitogen‑activated protein kinase reduces inflammation after 
coronary vascular injury in humans. Arterioscler Thromb Vasc Biol. 
2010;30(11):2256–63.
 26. Liang Y, Li X, Zhang X, Li Z, Wang L, Sun Y, Liu Z, Ma X. Elevated levels of 
plasma TNF‑alpha are associated with microvascular endothelial dysfunc‑
tion in patients with sepsis through activating the NF‑kappaB and p38 mito‑
gen‑activated protein kinase in endothelial cells. Shock. 2014;41(4):275–81.
 27. Curtis AM, Wilkinson PF, Gui M, Gales TL, Hu E, Edelberg JM. p38 mitogen‑
activated protein kinase targets the production of proinflammatory 
endothelial microparticles. J Thromb Haemost. 2009;7(4):701–9.
 28. Fan XY, Chen B, Lu ZS, Jiang ZF, Zhang SQ. Poly‑l‑arginine acts synergisti‑
cally with LPS to promote the release of IL‑6 and IL‑8 via p38/ERK signal‑
ing pathways in NCI‑H292 cells. Inflammation. 2016;39(1):47–53.
 29. Chirinos JA, Zambrano JP, Virani SS, Jimenez JJ, Jy W, Ahn E, Horstman 
LL, Castellanos A, Myerburg RJ, Ahn YS. Correlation between apoptotic 
endothelial microparticles and serum interleukin‑6 and C‑reactive protein 
in healthy men. Am J Cardiol. 2005;95(10):1258–60.
 30. Cui Y, Zheng L, Jiang M, Jia R, Zhang X, Quan Q, Du G, Shen D, Zhao X, 
Sun W, et al. Circulating microparticles in patients with coronary heart 
disease and its correlation with interleukin‑6 and C‑reactive protein. Mol 
Biol Rep. 2013;40(11):6437–42.
